We analyzed somatic loss of heterozygosity events in eight glioma tumor samples from individuals belonging to eight families (D, F, G, H, C, L, B, Q) (Supplementary Table 1) on variant-carrying genomic regions selected based on the WES data as well as on TP53 and literature variant regions, but no significant loss of heterozygosity was detected with regard to the identified variants in any of the patients. This evidence concerns the gene TP53 and central nervous system cancer.